COMMUNIQUÉS West-GlobeNewswire

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
03/03/2026
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet [...]
Human Appeal hosts global Grand Iftars, providing over 250,000 meals for vulnerable people this Ramadan
03/03/2026
Humanitarian charity running large scale Iftars for displaced peoples across Palestine, Iraq, Pakistan, Somalia, Sudan, Syria and Yemen MANCHESTER, United Kingdom, March 03, 2026 (GLOBE NEWSWIRE) -- Leading global [...]
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
03/03/2026
VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD, DME and RVO [...]
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
03/03/2026
SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
PathAI Receives U.S. FDA Breakthrough Device Designation for PathAssist Derm, an AI-Powered Pathology Solution to Transform Dermatopathology Workflow
03/03/2026
BOSTON, March 03, 2026 (GLOBE NEWSWIRE) -- PathAI, Inc., a global leader in artificial intelligence (AI)-powered pathology solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted [...]
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
03/03/2026
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care [...]
Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event
03/03/2026
HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, announced today that the Company, both in the [...]
Exagen Inc. to Participate in Upcoming Investor Conferences
03/03/2026
CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conferences: KeyBank [...]
LiveWorld Launches Integrated GEO, AIO and SEO Search Optimization for Healthcare and Pharma Brands
03/03/2026
A unified solution combining AI and SEO audits, prompt and keyword intelligence, and AI-optimized content creation to ensure brands lead in both organic search and AI-generated answers CAMPBELL, Calif. and NEW YORK, [...]
Hot Springs Arkansas Neurologist Kara Way Opens New Way Neurology
03/03/2026
HOT SPRINGS, Ark., March 03, 2026 (GLOBE NEWSWIRE) -- New Way Neurology is now open and serving patients at 100 Ridgeway St., Suite 2, in Hot Springs. The new practice is led by Board-certified neurologist Kara Way, MD [...]
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders
03/03/2026
TORONTO, March 03, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives [...]
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
03/03/2026
The Collaboration Framework marks Adial’s first step towards commercial partnership and establishing an exclusive European pathway as AD04 advances toward pivotal Phase 3 development GLEN ALLEN, Va., March 03, 2026 ( [...]
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
03/03/2026
NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through [...]
Journal of Analytical Toxicology Publishes Peer-Reviewed Validation Study Demonstrating Accuracy of Omega Laboratories’ Test Method for Detecting Marijuana in Breath Samples Using Cannabix Technologies’ Breath Collection Unit
03/03/2026
VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) and Omega Laboratories Inc (“Omega”) proudly announce [...]
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
03/03/2026
Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim’s reach with biopharma [...]
T-knife Therapeutics Announces Authorization of Clinical Trial Application for TK-6302, A Multi-Armored, CRISPR based T cell Therapy for Solid Tumors
03/03/2026
- Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiation SAN FRANCISCO and BERLIN, March 03, 2026 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a [...]
Inspire Medical Systems, Inc. to Present at the KeyBanc Capital Markets Healthcare Forum
03/03/2026
MINNEAPOLIS, March 03, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
03/03/2026
Randomized, placebo-controlled study to evaluate safety, tolerability, and potential for positive impact on lung function AUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a [...]
Prolium Bioscience Launches with $50 Million and Announces First Patients Dosed with PRO-203, a Potential Best-in-Class CD20xCD3 T-Cell Engager, for Severe Autoimmune Disease
03/03/2026
Initial $50M Series A investment from founding investor RTW Investments Proceeds will fund clinical development of PRO-203 in systemic sclerosis (SSc) and multiple additional severe autoimmune diseases NEW YORK, March [...]

Pages